EHA 2012 - European Hematology Association - June 2012
Chronic Myeloid Leukemia - CML
EHA 17 Amsterdam, 2012 - ABSTACT book
Some interesting abstracts for CML
PREGNANCY OUTCOMES AND TREATMENT REGIMENS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
EFFICACY AND SAFETY OF BOSUTINIB FOR PHILADELPHIA CHROMOSOME–POSITIVE LEUKEMIA IN OLDER VERSUS YOUNGER PATIENTS
BOSUTINIB VERSUS IMATINIB IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: 30-MONTH UPDATE OF THE BELA TRIAL
DEFINITIONS AND STANDARDISATION OF ‘COMPLETE’ MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA
CLINICAL AND BIOLOGICAL FEATURES OF PH CHRONIC MYELOID LEUKEMIA (CML) LONG SURVIVOR PATIENTS (MORE THAN 15 YEARS)
SUPERIOR EFFICACY OF NILOTINIB COMPARED WITH IMATINIB IN NEWLY DIAGNOSED PATIENTS WITH PH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTND 3-YEAR FOLLOW-UP
NILOTINIB INDUCES DEEPER MOLECULAR RESPONSES VS CONTINUED IMATINIB IN PATIENTS WITH PH CHRONIC MYELOID LEUKEMIA (CML) WITH DETECTABLE DISEASE AFTER = 2 YEARS ON IMATINIB: ENESTCMR 12-MONTH RESULTS
FRONTLINE TREATMENT OF PHILADELPHIA POSITIVE CHRONIC MYELOID LEUKEMIA WITH SEQUENTIAL ADMINISTRATION OF NILOTINIB 400 MG TWICE DAILY AND IMATINIB 400 MG ONCE DAILY: A PHASE 2 MULTICENTRIC STUDY
EARLY BCR-ABL TRANSCRIPT LEVELS PREDICT FUTURE MOLECULAR RESPONSE AND LONG-TERM OUTCOMES IN NEWLY-DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: ANALYSIS OF ENESTND 3-YEAR DATA
PACE: A PIVOTAL PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH CML AND PH ALL RESISTANT OR INTOLERANT TO DASATINIB OR NILOTINIB, OR WITH THE T315I MUTATION
PREGNANCY OUTCOMES AND TREATMENT REGIMENS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
EFFICACY AND SAFETY OF BOSUTINIB FOR PHILADELPHIA CHROMOSOME–POSITIVE LEUKEMIA IN OLDER VERSUS YOUNGER PATIENTS
BOSUTINIB VERSUS IMATINIB IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: 30-MONTH UPDATE OF THE BELA TRIAL
DEFINITIONS AND STANDARDISATION OF ‘COMPLETE’ MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA
CLINICAL AND BIOLOGICAL FEATURES OF PH CHRONIC MYELOID LEUKEMIA (CML) LONG SURVIVOR PATIENTS (MORE THAN 15 YEARS)
SUPERIOR EFFICACY OF NILOTINIB COMPARED WITH IMATINIB IN NEWLY DIAGNOSED PATIENTS WITH PH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTND 3-YEAR FOLLOW-UP
NILOTINIB INDUCES DEEPER MOLECULAR RESPONSES VS CONTINUED IMATINIB IN PATIENTS WITH PH CHRONIC MYELOID LEUKEMIA (CML) WITH DETECTABLE DISEASE AFTER = 2 YEARS ON IMATINIB: ENESTCMR 12-MONTH RESULTS
FRONTLINE TREATMENT OF PHILADELPHIA POSITIVE CHRONIC MYELOID LEUKEMIA WITH SEQUENTIAL ADMINISTRATION OF NILOTINIB 400 MG TWICE DAILY AND IMATINIB 400 MG ONCE DAILY: A PHASE 2 MULTICENTRIC STUDY
EARLY BCR-ABL TRANSCRIPT LEVELS PREDICT FUTURE MOLECULAR RESPONSE AND LONG-TERM OUTCOMES IN NEWLY-DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: ANALYSIS OF ENESTND 3-YEAR DATA
PACE: A PIVOTAL PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH CML AND PH ALL RESISTANT OR INTOLERANT TO DASATINIB OR NILOTINIB, OR WITH THE T315I MUTATION
